South Dakota Investment Council continued to hold its position in shares of Cempra, Inc. (NASDAQ:CEMP) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 706,207 shares of the biotechnology company’s stock at the end of the second quarter. South Dakota Investment Council owned 1.35% of Cempra worth $3,249,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. increased its holdings in Cempra by 92.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 103,848 shares of the biotechnology company’s stock worth $478,000 after acquiring an additional 49,820 shares in the last quarter. Swiss National Bank increased its holdings in Cempra by 35.0% in the 2nd quarter. Swiss National Bank now owns 82,230 shares of the biotechnology company’s stock worth $378,000 after acquiring an additional 21,300 shares in the last quarter. Federated Investors Inc. PA increased its holdings in Cempra by 251.4% in the 2nd quarter. Federated Investors Inc. PA now owns 67,771 shares of the biotechnology company’s stock worth $312,000 after acquiring an additional 48,485 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Cempra by 23.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 255,975 shares of the biotechnology company’s stock worth $1,178,000 after acquiring an additional 49,135 shares in the last quarter. Finally, State of Wisconsin Investment Board purchased a new stake in Cempra in the 2nd quarter worth $166,000. 49.76% of the stock is owned by hedge funds and other institutional investors.
Cempra, Inc. (CEMP) opened at 3.15 on Friday. Cempra, Inc. has a 12 month low of $2.55 and a 12 month high of $26.95. The firm’s market cap is $165.40 million. The stock’s 50 day moving average is $3.40 and its 200 day moving average is $3.81.
Cempra (NASDAQ:CEMP) last issued its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.09. Cempra had a negative return on equity of 53.99% and a negative net margin of 560.40%. The firm had revenue of $0.86 million for the quarter, compared to analyst estimates of $3.58 million. During the same period last year, the company earned ($0.51) EPS. The firm’s quarterly revenue was down 74.9% on a year-over-year basis. On average, equities analysts forecast that Cempra, Inc. will post ($1.01) earnings per share for the current year.
Several equities research analysts recently commented on CEMP shares. Zacks Investment Research raised shares of Cempra from a “hold” rating to a “buy” rating and set a $3.50 price target for the company in a report on Friday, August 11th. Jefferies Group LLC reissued a “hold” rating and issued a $3.00 price target on shares of Cempra in a report on Thursday, May 25th. Stifel Nicolaus reissued a “hold” rating and issued a $4.00 price target on shares of Cempra in a report on Thursday, August 10th. Roth Capital lowered shares of Cempra from a “buy” rating to a “neutral” rating and cut their price target for the stock from $8.00 to $4.00 in a report on Thursday, August 10th. Finally, ValuEngine cut shares of Cempra from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Four investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $11.38.
COPYRIGHT VIOLATION WARNING: “South Dakota Investment Council Holds Position in Cempra, Inc. (CEMP)” was reported by Markets Daily and is the property of of Markets Daily. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.themarketsdaily.com/2017/09/10/south-dakota-investment-council-holds-position-in-cempra-inc-cemp.html.
Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).
Receive News & Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.